Last reviewed · How we verify
A Phase II, Randomized, Double-blind, Placebo-controlled Dose-ranging Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 5 to 20 mg/day will be studied.
Details
| Lead sponsor | Hoffmann-La Roche |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Start date | 2001-12 |
| Completion | 2003-12 |
Conditions
- Diabetes
Interventions
- Ro 205-2349
Countries
United States, Bulgaria, Canada, Estonia, Latvia, Lithuania, Mexico, Panama, Puerto Rico, Romania, United Kingdom